Oncotarget

Research Papers:

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production

Kevin P. Kotredes, Roshanak Razmpour, Evan Lutton, Mercedes Alfonso-Prieto, Servio H. Ramirez and Ana M. Gamero

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2019; 10:2675-2692. https://doi.org/10.18632/oncotarget.26848

Metrics: PDF 288 views  |   HTML 265 views  |   ?  


Abstract

Kevin P. Kotredes1, Roshanak Razmpour2, Evan Lutton2, Mercedes Alfonso-Prieto3,4,5, Servio H. Ramirez2 and Ana M. Gamero1

1 Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA

2 Department of Pathology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA

3 Department of Inorganic and Organic Chemistry, University of Barcelona, Barcelona, Spain

4 Computational Biomedicine, Institute for Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich, Jülich, Germany

5 C. and O. Vogt Institute for Brain Research, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

Correspondence to:

Ana M. Gamero,email: gameroa@temple.edu

Keywords: glioblastoma; IDH2; tumorigenesis; chemotherapy; biomarker

Received: October 06, 2018     Accepted: March 23, 2019     Published: April 12, 2019

ABSTRACT

The family of isocitrate dehydrogenase (IDH) enzymes is vital for cellular metabolism, as IDH1 and IDH2 are required for the decarboxylation of isocitrate to α-ketoglutarate. Heterozygous somatic mutations in IDH1 or IDH2 genes have been detected in many cancers. They share the neomorphic production of the oncometabolite (R)-2-hydroxyglutarate [(R)-2-HG]. With respect to IDH2, it is unclear whether all IDH2 mutations display the same or differ in tumorigenic properties and degrees of chemosensitivity. Here, we evaluated the three most frequent IDH2 mutations occurring in cancer. The predicted changes to the enzyme structure introduced by these individual mutations are supported by the observed production of (R)-2-HG. However, their tumorigenic properties, response to chemotherapeutic agents, and baseline activation of STAT3 differed. Paradoxically, the varying levels of endogenous (R)-2-HG produced by each IDH2 mutant inversely correlated with their respective growth rates. Interestingly, while we found that (R)-2-HG stimulated the growth of non-transformed cells, (R)-2-HG also displayed antitumor activity by suppressing the growth of tumors harboring wild type IDH2. The mitogenic effect of (R)-2-HG in immortalized cells could be switched to antiproliferative by transformation with oncogenic RAS. Thus, our findings show that despite their shared (R)-2-HG production, IDH2 mutations are not alike and differ in shaping tumor cell behavior and response to chemotherapeutic agents. Our study also reveals that under certain conditions, (R)-2-HG has antitumor properties.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26848